An Introduction to Gout
Gout, the most common inflammatory arthritis worldwide, is characterized by intense pain and impaired quality of life. Management strategies include weight management, increasing exercise and reducing alcohol consumption to reduce uric acid levels, as well as treatment with xanthine oxidase inhibitors. Other urate-lowering strategies include the selective uric acid reabsorption inhibitors lesinurad and arhalofenate. An acute attack of gout is likely to require treatment with a nonsteroidal anti-inflammatory drug (NSAID) or colchicine. Emerging anti-inflammatory strategies involving targeted anti-interleukin (IL) therapy appear effective in reducing the pain of acute attacks as well as preventing recurrent attacks.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Michael Pillinger, ACR 2022: An analysis of neutrophil-to-lymphocyte ratio changes in patients with uncontrolled gout receiving pegloticase therapy
Pegloticase is a urate-lowering therapy that is approved for the treatment of gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss whether urate lowering therapy impacted the neutrophil-to-lymphocyte ratio in patients with uncontrolled gout. This information is brought to you by Touch Medical […]
Michael Pillinger, ACR 2022: The neutrophil-to-lymphocyte ratio as a biomarker for gout flares
The neutrophil-to-lymphocyte ratio (NLR) is a biomarker that is increased in patients with active gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss the pathophysiology of gout flares and the rationale for the NLR as a biomarker for systemic inflammation in gout. This […]
Immunomodulation with Methotrexate Improves Treatment Response to Pegloticase in Uncontrolled Gout
touchREVIEWS in RMD. 2022;1(2):42–3 DOI: https://doi.org/10.17925/RMD.2022.1.2.42
Gout is a systemic and underserved disease. Many primary care physicians are treating gout as an episodic disease, providing therapies for only the acute attack.1 As a result of this, many patients with gout are languishing without even being given simple, oral, urate-lowering therapies.2 Additionally, patients who are prescribed an oral urate-lowering therapy are often underdosed and/or […]
John Botson, EULAR 2022: Pegloticase and Methotrexate Co-therapy in Gout – Findings from the MIRROR Study
The FDA has recently approved pegloticase injection co-administered with methotrexate in uncontrolled gout following the findings from the MIRROR randomized clinical trial presented at EULAR 2022. touchIMMUNOLOGY were delighted to speak with Dr. John K. Botson (Orthopedic Physicians Alaska, Anchorage, AK, USA) to discuss the rationale for combining methotrexate with pegloticase in the treatment of […]
Robert Terkeltaub, ACR 2021: Tigulixostat for the Treatment of Gout with Hyperuricemia
It was a pleasure to meet with Professor Robert Terkeltaub (UC San Diego, San Diego, California, USA) to discuss the efficacy and safety findings from the phase 2 study of tigulixostat in gout with hyperuricemia (NCT03934099). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, […]
Thomas MacDonald, ACR 2020 – Cardiovascular Safety of Febuxostat and Allopurinol in Chronic Gout: The FAST Study (Part 2)
In Part 2, Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) discusses further how the results of the FAST study compared to another study, the CARES trial, which also investigated the cardiovascular risks associated with these two treatments. The late-breaking abstract entitled ‘Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: […]
Thomas MacDonald, ACR 2020 – Cardiovascular safety of Febuxostat and Allopurinol in Chronic Gout: The FAST Study (Part 1)
Following concerns related to the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. Here we talk to Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) about the results of this study and what they mean. The late-breaking abstract entitled ‘Long Term Cardiovascular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!